anticoagulants, oral factor Xa inhibitors, apixaban, 2.5 or 5 mg twice daily, extended treatment for one year after 6-12 months
DISEASE INTERVENTION COMPARISON RESULTS
N Engl J Med. 2013 Feb 21;368(8):699-708 Randomized Controlled Trial, Multicenter Study
IN thromboembolic disease, idiopathic The Use of
anticoagulants, oral factor Xa inhibitors, apixaban, 2.5 or 5 mg twice daily, extended treatment for one year after 6-12 months
As Treatment, Chronic
Is better Than
non extended treatment, only 6-12 months, placebo afterwards
To reduce new episodes of symptomatic venous thromboembolism (1.7% apixaban both doses VS 8.8% placebo). Apixaban increased nonmajor bleeding (3-4% apixaban VS 2% placebo) but not major bleeding (0.2% apixaban VS 0.5% placebo)